Back to Topics
Interventional
Navigational Bronchoscopy & Robotic Bronchoscopy
Added by Dr. Andrew · Last updated 2024-01-15
Overview
Navigational bronchoscopy technologies extend the reach of flexible bronchoscopy to peripheral pulmonary lesions beyond the direct visualization range. Electromagnetic navigation (EMN) and robotic-assisted bronchoscopy (Ion, Monarch) enable biopsy of peripheral nodules with improved reach and stability.
Key Points
- 1Electromagnetic navigation (EMN): superDimension — virtual bronchoscopy navigation to peripheral lesion
- 2Robotic bronchoscopy: Ion (Intuitive) and Monarch (Auris/J&J) — improved stability and reach vs EMN
- 3Diagnostic yield: ~70–80% for robotic bronchoscopy vs ~60–70% for EMN vs ~20–30% for standard TBB
- 4CBCT (cone-beam CT) confirmation: real-time CT during procedure to confirm tool-in-lesion
- 5Indications: peripheral pulmonary nodules ≥8–10 mm not accessible by standard bronchoscopy
- 6Complications: pneumothorax (~2–4%), bleeding, infection
Clinical Pearls
- Bronchus sign on CT: bronchus leading to lesion — predicts higher yield for bronchoscopic biopsy
- CBCT + robotic bronchoscopy: highest yield combination for peripheral lesions
- Fiducial marker placement: can be done bronchoscopically for SBRT targeting
- Lesion size <10 mm: yield drops significantly — consider CT-guided biopsy instead
Board High-Yield
Exam Focus- NAVIGATE trial: EMN diagnostic yield ~73% for peripheral lesions
- Robotic bronchoscopy (Ion): PRECISION-1 trial — 81% diagnostic yield
- Bronchus sign: CT finding predicting higher bronchoscopic yield
- CBCT confirmation: improves yield by confirming tool-in-lesion before biopsy
- Alternative for peripheral lesions: CT-guided transthoracic needle biopsy (higher yield but higher PTX risk)
ABIM Exam Weight
5%
Interventional Pulmonology represents approximately 5% of the PCCM certification exam.